|
|
|
|
|
|
|
11.11.25 - 01:06
|
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR (Business Wire)
|
|
|
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC (“GTCR”) from consummating the proposed acquisition of the Company by an affiliate of GTCR (the “Merger”).
Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to consummate the Merger prior to 5:00 p.m. Central time on Monday, November 17. It also remains subject to the satisfaction or waiver of closing conditions set forth in the agreement related to the Merger (the “merger agreement”), including (1) the absence ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.08.25 - 13:03
|
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance (Business Wire)
|
|
|
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025.
Third Quarter Fiscal 2025 Financial Summary
Total Revenue of $29.6 million, a decrease of 3% year-over-year
Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”) license fee revenue(1) of $29.6 million, an increase of 1% year-over-year
GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period
Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the prior-year period
Third Quarter Business Highlights
On April 3, 2025, Surmodics announced the commercial release of the Pounce XL Thrombectomy System, enabling rapid non-surgical clot removal in iliac and femoral arteries. With the addition of Pounce XL, Surmodics' fully mechanical Pounce T...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.25 - 13:03
|
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance (Business Wire)
|
|
|
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025.
Second Quarter Fiscal 2025 Financial Summary
Total Revenue of $28.1 million, a decrease of 12% year-over-year
Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”) license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year
GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period
Adjusted EBITDA(2) of $1.9 million, compared to $4.8 million in the prior-year period
Second Quarter and Recent Business Highlights
On February 3, 2025, Surmodics announced the successful early clinical use of the Pounce™ XL Thrombectomy System, which is intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5...
|
|
|
29.04.25 - 00:03
|
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 (Business Wire)
|
|
|
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30.
Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments.
About Surmodics, Inc.
Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
